Phase 4
Completed N=68
Effects of N-acetylcysteine on Low T3 Syndrome
Myocardial Infarction · Euthyroid Sick Syndrome · Heart Failure
Source: ClinicalTrials.gov NCT01501110 ↗
Enrolled (actual)
68
Serious AEs
0.0%
Results posted
Mar 2015
Primary outcomePrimary: Serum T3 Levels at 48 Hours — 93.5; 96.5 ng/dL
Summary
The propose of this study is to determine whether N-acetylcysteine is effective in reversing the changes in thyroid hormones seen in critical illness, known as the low T3 syndrome.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Serum T3 Levels at 48 Hours |
93.5; 96.5 | — |
Eligibility Criteria
Inclusion Criteria
- diagnosis of acute myocardial infarction with less than 12 hours of evolution
- reperfusion therapy (primary angioplasty)
Exclusion Criteria
- Thyroid disease
- Chronic renal disease with renal replacement therapy
- hepatic insufficiency
- immunosuppression
Data sourced from ClinicalTrials.gov (NCT01501110). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.